Tandem mass spectrometry method for the quantification of serum busulfan

Therapeutic Drug Monitoring

Volumn 27, Issue 5, 2005, Pages 625-629

  Kellogg, M D ^a   Law, T ^a   Sakamoto, M ^a   Rifai, N ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Busulfan; Mass spectrometry; Therapeutic drug monitoring

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BROMPHENIRAMINE; BUSULFAN; CARBAMAZEPINE; CHLORAMPHENICOL DERIVATIVE; CLONAZEPAM; DEXTROMETHORPHAN; DIGITOXIN; DIGOXIN; DISOPYRAMIDE; ETHOSUXIMIDE; FELBAMATE; IBUPROFEN; ITRACONAZOLE; MEPHENYTOIN; PARACETAMOL; PEMOLINE; PEMOLINE MAGNESIUM; PHENYLPROPANOLAMINE; PRIMIDONE; THEOPHYLLINE; TRIMETHADIONE; UNINDEXED DRUG; VALPROIC ACID;

ACCURACY; ALKYLATION; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INDIVIDUALIZATION; NONHUMAN; PRIORITY JOURNAL; PRODUCT RECOVERY; QUANTITATIVE ASSAY; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 26444477714     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000173372.04945.7b     Document Type: Article

References (17)

1. Brodsky R, Topolsky D, Crilley P, et al. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen. Am J Clin Oncol. 1990;13:221-225.
2. Hasegawa S, Horibe K, Kawabe T, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transplant. 1998;22:1191-1197.
3. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778-783.
4. Grochow LB, Jones RJ, Brandrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61.
5. Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan vs. total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. Transplant Proc. 1994;26:1831-1832.
6. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20:18-25; quiz 6.
7. Rifai N, Sakamoto M, Lafi M, et al. Measurement of plasma busulfan concentration by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit. 1997;19:169-174.
8. Quernin MH, Poonkuzhali B, Montes C, et al. Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol. J Chromatogr B Biomed Sci Appl. 1998;709:47-56.
9. Murdter TE, Coller J, Claviez A, et al. Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. Clin Chem. 2001;47:1437-1442.
10. Heggie JR, Wu M, Burns RB, et al. Validation of a high-performance liquid chromatographic assay method for pharmacokinetic evaluation of busulfan. J Chromatogr B Biomed Sci Appl. 1997;692:437-444.
11. Chen TL, Grochow LB, Hurowitz LA, et al. Determination of busulfan in human plasma by gas chromatography with electron-capture detection. J Chromatogr. 1988;425:303-309.
12. Annesley TM. Ion suppression in mass spectrometry. Clin Chem. 2003;49:1041-1044.
13. Chattergoon DS, Saunders EF, Klein J, et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant. 1997;20:347-354.
14. Balasubramanian P, Chandy M, Krishnamoorthy R, et al. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Bone Marrow Transplant. 2001;28:821-825.
15. Hassan M, Fasth A, Gerritsen B, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant. 1996;18:843-850.
16. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood. 1992;79:2475-2479.
17. Dupuis LL, Najdova M, Saunders EF. Retrospective appraisal of busulfan dose adjustment in children. Bone Marrow Transplant. 2000;26:1143-1147.